Sugi Predict

Sugi Predict / Compounds / SCHEMBL20566987

SCHEMBL20566987

SCHEMBL20566987

CC(C)(C)OC(=O)N1CCC(OCc2cc(Cl)cc(Oc3ccc(Cl)cc3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 3/20 0.48
▸ GPR119 Q8TDV5 4/20 0.44
▸ CACNB4 O00305 2/20 0.44
▸ CACNA1A O00555 2/20 0.44
▸ CACNA1G O43497 2/20 0.44
▸ CACNG3 O60359 2/20 0.44
▸ CACNA1F O60840 2/20 0.44
▸ CACNA1H O95180 2/20 0.44
▸ CACNB3 P54284 2/20 0.44
▸ CACNA2D1 P54289 2/20 0.44
▸ CACNG7 P62955 2/20 0.44
▸ CACNA1B Q00975 2/20 0.44
▸ CACNA1D Q01668 2/20 0.44
▸ CACNB1 Q02641 2/20 0.44
▸ CACNG1 Q06432 2/20 0.44
▸ CACNB2 Q08289 2/20 0.44
▸ CACNA1S Q13698 2/20 0.44
▸ CACNA1C Q13936 2/20 0.44
▸ CACNA1E Q15878 2/20 0.44
▸ CACNA2D4 Q7Z3S7 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16759410 0.87 STS (0.59) STSGPR119ALDH1A1SMN1; SMN2FAAH
SCHEMBL20570917 0.85 FAAH (0.48) FAAHMGLL
SCHEMBL20566281 0.83 FAAH (0.58) FAAHMGLL
SCHEMBL30302134 0.83 FAAH (0.58) FAAHMGLL
SCHEMBL20567770 0.81 FAAH (0.58) STSMEN1KMT2AALDH1A1LMNA
SCHEMBL651653 0.79 STS (0.49) STSGPR119CACNB4CACNA1ACACNA1G
SCHEMBL651652 0.79 STS (0.49) STSGPR119CACNB4CACNA1ACACNA1G
SCHEMBL654435 0.79 STS (0.49) STSGPR119CACNB4CACNA1ACACNA1G
SCHEMBL25830170 0.77 FAAH (0.63) FAAHMGLL
SCHEMBL2793124 0.77 GPR119 (0.65) STSGPR119CACNB4CACNA1ACACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 — — US disclosed
CN-116473965-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2025-03-18 — — CN disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 — — CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 — — US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 — — EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 — — EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 — — US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 — — US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 — — US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 — — US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 — — US disclosed
EP-3630744-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-08 — — EP disclosed
CN-110678456-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 — — CN disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 — — US disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 — — US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL STS 1749/4885GPR119 308/4885CACNB4 3519/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL STS 1749/4885GPR119 308/4885CACNB4 3519/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL STS 1926/4885GPR119 353/4885CACNB4 3515/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL STS 1749/4885GPR119 308/4885CACNB4 3519/4885
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL STS 1749/4885GPR119 308/4885CACNB4 3519/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL STS 1926/4885GPR119 353/4885CACNB4 3515/4885
US-10927105-B1 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL STS 1749/4885GPR119 308/4885CACNB4 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.